# US 8,569,059 B2 · Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,059 B2
- Document ID: US8569059B2
- Status: Granted
- Kind: B2
- Application number: 12/376,019
- Filed: 2007-08-02
- Published: 2011-12-22
- Granted: 2013-10-29
- Earliest claimed: 2006-08-02
- Assignees: NewSouth Innovations Pty Limited
- Applicants: Bruce Milne Hall; Suzanne J. Hodgkinson
- Inventors: Bruce Milne Hall; Suzanne J. Hodgkinson
- Web page: https://patentgrep.com/patent/US8569059B2

## CPC

- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a method of identifying CD4+ CD25+ T cells activated to an antigen in a population of T cells, comprising identifying CD4+ CD25+ T cells which express CD8. The invention also relates to a method of isolating CD4+ CD25+ T cells activated to an antigen comprising isolating CD4+ CD25+ T cells which express CD8. The invention also relates to a method of increasing tolerance to an antigen in a subject comprising administering CD4+ CD25+ T cells which express CD8.

## Claims

### Claim 1

A method of preparing a population of activated CD4+CD25+CD8+ T cells comprising:
(a) providing a population of isolated CD4+CD25+ T cells;
(b) contacting the population of isolated CD4+CD25+ T cells with an alloantigenic antigen presenting cell, in the presence of a factor selected from the group consisting of IL-2 and IL-4, for a sufficient time to permit proliferation of the CD4+,CD25+ T cells; and
(c) isolating CD4+CD25+CD8+ T cells from the proliferated CD4+CD25+ T cells.

### Claim 2 (depends on 1)

The method of claim 1, comprising the further step, after step (c), of (d) growing the CD4+CD25+CD8+ T cells in the presence of at least one factor selected from the group consisting of IL-2, IL-4, IL-5, IL-12, IL-23, IL-10, IFN-gamma, TGF-beta, and a nitric oxide inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the factor is IL-2.

### Claim 4 (depends on 2)

The method of claim 2, wherein the factor is IL-4.

### Claim 5 (depends on 2)

The method of claim 2, wherein the factor is IL-5.

### Claim 6 (depends on 2)

The method of claim 2, wherein the factor is IL-12.

### Claim 7 (depends on 2)

The method of claim 2, wherein the factor is IFN-gamma.

### Claim 8 (depends on 2)

The method of claim 2, wherein the factor is IL-10.

### Claim 9 (depends on 2)

The method of claim 2, wherein the factor is IL-23.

### Claim 10 (depends on 2)

The method of claim 2, wherein the factor is TGF-beta.

### Claim 11 (depends on 2)

The method of claim 2, wherein the factor is a nitric oxide inhibitor.